Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.
Neumora Therapeutics (NASDAQ:NMRA) was given a new $6.00 price target on by analysts at Mizuho.
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones [Yahoo! Finance]